Further analysis of immune-stimulating factors (Figure 6D) revealed that in tumors such as LGG, PRAD, and BRCA, the expression of PLAG1 was significantly positively correlated with immune-stimulating factors like CD48, CD27, and TMIGD2, which may enhance anti-tumor immune responses. Here, TMIGD2 is linked to neoplasm.